Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma.

Cancer treatment and research communications - 1 Jan 2021

Park Robin, Al-Jumayli Mohammed, Miller Kirk, Saeed Azhar, Saeed Anwaar

Abstract excerpt

Advanced pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor with an abysmal prognosis. Beyond the first-line setting, treatment for advanced PDAC is limited and suboptimal. Also, the efficacy of epidermal growth factor receptor (EGFR) targeted therapy alone in the chemo-refractory setting in PDAC tumors harboring druggable EGFR mutations is unclear. Here we describe the case of a patient with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Erlotinib Hydrochloride

Share to Fluorouracil

Share to Leucovorin

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 33611092
DOI: 10.1016/j.ctarc.2021.100342

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma.PMID 33611092Read ↗

Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.Semantic proximity Read ↗

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.Semantic proximity Read ↗

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.Semantic proximity Read ↗

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.Semantic proximity Read ↗

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.Semantic proximity Read ↗

Targeted Therapy for BRAF V600E Positive Pancreatic Adenocarcinoma: Two Case Reports.Semantic proximity Read ↗

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.Semantic proximity Read ↗

Remarkable response of BRAFV600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case reportSemantic proximity Read ↗

Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer.Semantic proximity Read ↗

Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review.Semantic proximity Read ↗

Acquired EGFR Resistance Mutation C797S in Pancreatic Adenocarcinoma Following Partial Response to Third-Generation EGFR Inhibitor Therapy.Semantic proximity Read ↗

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.